SEC Form 4	
------------	--

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287

0.5

See

See

footnote<sup>(2)</sup> See

footnote<sup>(3)</sup>

footnote<sup>(4)</sup> See

I

T

T

Estimated average burden

hours per response:

	Check this box if no longer subject to
$\square$	Section 16. Form 4 or Form 5
$\cup$	Section 16. Form 4 or Form 5 obligations may continue. See
	Instruction 1(b).

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

								1		*					
1. Name and Address of Reporting Person <sup>*</sup> Ostertag Eric				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Poseida Therapeutics, Inc.</u> [PSTX ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Osteriag Eric</u>											Director	X 10%	Owner		
-										Officer (give title		er (specify			
(Last)	(First)	3. Date of Earliest Transaction (Month/Day/Year)							below)	belo	,				
C/O POSEIDA	THERAPEU	FICS, INC.		08/06/2021							Chief Executive Officer				
9390 TOWNE CENTRE DRIVE, STE 200															
9390 TO WINE	CENTRE DRI	IVE, 51E 200													
(2)				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SAN DIEGO CA 92121										X Form filed by One Reporting Person					
										Form filed by More than One Reporting					
										Person					
(City)	(State)	(Zip)													
		Tabla I Na	n Deriv				Die	nood of		oficially	Ourread				
		Table I - No	on-Deriva	ative s	Securities Acq	uirea	, Dis	posed of,	or Ben	encially	Owned	-			
Date			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Disposed Of (			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)		
Common Stock			08/06/2	2021		М		111,149	A	\$9.15	654,134	D			
Common Stock											3,738,475	I	See footnote <sup>(1)</sup>		

Common	Common Stock										200,	696		ootnote <sup>(5)</sup>	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$9.15	08/06/2021		м			111,149	(6)	02/03/2031	Common Stock	111,149	\$0.00	778,044	D	

Explanation of Responses:

**Common Stock** 

Common Stock

**Common Stock** 

1. The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.

2. The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.


3. The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.

4. The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.

5. The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.

6. 12.5% of the shares subject to the stock option vested and became exercisable on the August 4, 2021, and the remaining shares will vest in 42 equal monthly installments thereafter.

Remarks:



\*\* Signature of Reporting Person

Date

08/10/2021

3,430,847

629,194

961,445

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.